Trial: 202008123

A Phase I First-in-human Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination With Durvalumab (MEDI4736) in Participants With Advanced Solid Tumours

Phase

I (Cancer Control)

Principal Investigator

Bagegni, Nusayba

Disease Site

Breast; Cervix; Ill-Defined Sites; Kidney; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Stomach

Learn more about this study at: clinicaltrials.gov